A research team from Nanyang Technological University, Singapore (NTU Singapore) and Tan Tock Seng Hospital (TTSH) have invented a smart handheld medical device that could enable early intervention for patients with congestive heart failure.
The portable innovation, which resembles a stethoscope, is made up of an acoustic sensor connected to a smartphone. It enables early intervention by allowing patients to check for excess fluid in the lungs at home. Fluid accumulation in the lungs, which causes breathlessness, is a common symptom of congestive heart failure.
One in five people worldwide run the risk of developing congestive heart failure, and this prevalence increases with age. As there is no cure for the ailment, patients can only monitor their health closely with lifestyle changes or medication to prevent their heart function from deteriorating irreversibly.
Currently, patients can only check for fluid accumulation in the lungs by going for a clinical examination, which can be considerably subjective, or through imaging modalities and serum biomarker tests, which are costly and take a longer time.
The non-invasive device built by a team led by NTU Associate Professor Ser Wee and TTSH Associate Professor David Foo circumvents these problems with its portability, ease of use and quick results. Currently a prototype, the device is able to detect any excess fluid in the lungs in 10 seconds once placed on the patient’s chest or back.
In a pilot study using lung sounds recorded from TTSH’s congestive heart failure patients, Assoc Prof Ser and his team found the device to have over 92 per cent accuracy in identifying patients with the condition – comparable to existing ‘gold standard’ diagnosis methods such as X-rays and CT scans. The findings were first presented at the 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
Associate Professor Foo, Head of Cardiology at TTSH, said, “Patients can monitor their condition at home and use the device whenever they feel slightly breathless at home. It is potentially a game-changer in the management of ambulatory heart failure patients. It can also provide a rapid and accurate acute diagnosis of heart failure in situations of undifferentiated shortness of breath symptoms.”
Associate Professor Ser from NTU’s School of Electrical and Electronic Engineering added, “Currently, such diagnosis can only be conducted through clinical examination, which cannot be made frequently. Our smart medical device can be used by anyone, anywhere and any number of times, which will enable the possibility of early intervention of congestive heart failure.
“The next wave of MedTech (medical technology) start-ups will see the massive proliferation of smart medical devices that rely on artificial intelligence (AI) and sensing technologies, such as the one we invented, and that will enable personalised self-assessment and screening of cardiopulmonary and other diseases, and revolutionise the way healthcare is managed in future.”
How it works
In congestive heart failure, the diseased or overworked heart ventricle is unable to pump out enough of the blood it receives from the lungs. This causes pressure to build up first in the heart, then in the veins and capillaries in the lungs. The pressure then pushes fluid back through the capillary walls and into the air sacs of the lungs.
As a result, when air passes through these fluid-filled air sacs, crackles can be heard from the lungs. Depending on the intensity, a crackle may sound like salt added to a hot pan, or Velcro being torn apart. Based on this principle, Prof Ser and his team found a unique set of features that can be used to identify characteristics of sounds unique to patients with fluid accumulation in the lungs. They then developed a proprietary AI algorithm capable of identifying and processing these signals to determine if there is fluid accumulation in the lungs.
The smart medical device developed by NTU and TTSH first picks up breathing sounds through a sound sensor. Through a mobile app, the sound signals are then sent to a server located in the cloud. The NTU-developed algorithm stored in the cloud then processes these sound signals, and the results are shown on the mobile app. This whole process takes about 10 seconds to complete.
Following two rounds of tests with samples collected from 86 patients, the team is now running a third round of tests on the device to further validate its sensitivity and specificity.
A major pharmaceutical company, a healthcare MNC and a local healthcare company have approached the team to explore the possibility of collaborations.
The Latest on: Congestive heart failure
via Google News
The Latest on: Congestive heart failure
- HED Completes Design for Max and Debra Ernst Heart Center at Beaumont Hospitalon October 13, 2019 at 8:15 am
Heart Failure Clinics are not yet common around the U.S., with only a handful built to-date mostly in academic health systems. Beaumont Hospital has been a longtime leader in cardiovascular care and ...
- Hires, Roberton October 12, 2019 at 9:00 pm
Hires, Robert, - 88, of Beach Havens Gardens, passed on August 9th, 2019 from congestive heart failure at his home in Beach Haven Gardens, New Jersey. Born on December 6th, 1930 "Bob" was the third ...
- Coroner finds PG&E not at fault in Pollock Pines deathon October 12, 2019 at 4:22 pm
VICKI: MARIE EXPLAINS ROBERT MARDIS SENIOR SUFFERED FROM SERIOUS HEALTH ISSUES. >> HE HAD COPD AND HE HAD CONGESTIVE HEART FAILURE. IF IT SNOWED, IF IT WAS TOO COLD, IF THERE WAS A FIRE -- ANYTHING ...
- California Man Dependent on Oxygen Died 12 Minutes After PG&E Power Shutoffon October 11, 2019 at 6:16 pm
The family of Robert Mardis Sr., 67, said he was suffering from COPD and congestive heart failure, according to the Sacramento Bee. The El Dorado County Fire Department said Mardis was hooked up to ...
- New drug Aliskiren shows promise for heart failure patientson October 8, 2019 at 10:37 pm
Congestive heart failure, as it is properly called, affects over 5 million Americans, and is caused by a failure of the heart muscle to pump blood strongly enough to supply the body with enough ...
- Drug Improves Survival Rates In Heart Failure Patientson October 8, 2019 at 8:37 pm
Aliskiren, the drug that inhibits the enzyme that regulates blood pressure, delays the progression of congestive heart failure and improve survival rates, according to preclinical studies conducted by ...
- Aliskiren drug can delay progression of congestive heart failure, lengthen survival rateson October 8, 2019 at 2:27 pm
Researchers at the University of Arizona College of Medicine - Phoenix have shown for the first time in preclinical studies that Aliskiren, a drug that inhibits the enzyme that regulates blood ...
- Research shows drug can extend survival rates for heart failure patientson October 8, 2019 at 1:11 pm
Researchers at the University of Arizona College of Medicine—Phoenix have shown for the first time in preclinical studies that Aliskiren, a drug that inhibits the enzyme that regulates blood pressure, ...
- BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patientson October 8, 2019 at 12:29 am
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ...
via Bing News